Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium
View Publication
Export 
BiBTeXBACKGROUND The \textquotedblGENetIcs of sUbSequent Coronary Heart Disease\textquotedbl (GENIUS-CHD) consortium was established to facilitate discovery and validation of genetic variants and biomarkers for risk of subsequent CHD events, in individuals with established CHD. METHODS The consortium currently includes 57 studies from 18 countries, recruiting 185,614 participants with either acute coronary syndrome, stable CHD or a mixture of both at baseline. All studies collected biological samples and followed-up study participants prospectively for subsequent events. RESULTS Enrollment into the individual studies took place between 1985 to present day with duration of follow up ranging from 9 months to 15 years. Within each study, participants with CHD are predominantly of self-reported European descent (38%-100%), mostly male (44%-91%) with mean ages at recruitment ranging from 40 to 75 years. Initial feasibility analyses, using a federated analysis approach, yielded expected associations between age (HR 1.15 95% CI 1.14-1.16) per 5-year increase, male sex (HR 1.17, 95% CI 1.13-1.21) and smoking (HR 1.43, 95% CI 1.35-1.51) with risk of subsequent CHD death or myocardial infarction, and differing associations with other individual and composite cardiovascular endpoints. CONCLUSIONS GENIUS-CHD is a global collaboration seeking to elucidate genetic and non-genetic determinants of subsequent event risk in individuals with established CHD, in order to improve residual risk prediction and identify novel drug targets for secondary prevention. Initial analyses demonstrate the feasibility and reliability of a federated analysis approach. The consortium now plans to initiate and test novel hypotheses as well as supporting replication and validation analyses for other investigators.
DOI: 10.1161/CIRCGEN.119.002470
Projects: Genetical Statistics and Systems Biology
Publication type: Journal article
Journal: Circulation. Genomic and precision medicine
Human Diseases: No Human Disease specified
Citation: Circ: Genomic and Precision Medicine 12(4)
Date Published: 1st Apr 2019
Registered Mode: imported from a bibtex file
Export PNG
Download
Submitter
Views: 729
Created: 15th Sep 2020 at 08:43
Last updated: 7th Dec 2021 at 17:58
TagsThis item has not yet been tagged.
AttributionsNone
Related items
The group is interested in omic-level studies including the genome, methylome, transcriptome, and metabolome of the general population as well as of various diseases including cardiovascular diseases, pneumonia, sepsis, obesity, and brain cancers. Additionally, we aim at transfering results of biomathematical model simulations into clinical practice e.g. by haematopoietic growth-factor opimization during cytotoxic chemotherapy and optimization of EPO applications in chronic kidney disease.
The ...
Programme: This Project is not associated with a Programme
Public web page: http://www.imise.uni-leipzig.de/en/Groups/GenStat/
Start date: 1st Jan 2013
https://orcid.org/0000-0002-5307-6936
Projects: LIFE Heart, LIFE - Leipzig Research Center for Civilization Diseases, HaematoOpt - Individualized model-based managing of the next-cycle thrombopenia of CHOEP/CHOP treated patients based on platelets dynamics during the previous cycles, e:Med, Genetical Statistics and Systems Biology, Task Force COVID-19 Leipzig, NFDI4Health
Institutions: Institute for Medical Informatics, Statistics and Epidemiology (IMISE)
Markus Scholz Scientific Speaker Institution Institut für Medizinische Informatik, Statistik und Epidemiologie Universität Leipzig Härtelstraße 16-18 04107 Leipzig
